Boehringer Ingelheim· @Boehringer · X·· 2025-10-17AI 评分18
AI 导读
#NEWS：HER2（ERBB2）突变晚期非小细胞肺癌（NSCLC）患者的新数据亮相 #ESMO25。 这些进展有望满足患者未被满足的需求。 了解更多：https://go.boehringer.com/QpvyH #LifeForward #Oncology
正文
#NEWS: New data for patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) at #ESMO25.
These advancements have the potential to fulfill patients’ unmet needs.
Learn more: https://go.boehringer.com/QpvyH
#LifeForward #Oncology
来源：Boehringer Ingelheim · x.com